Article(id=1329914781051498685, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329914740324807335, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2024.06.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1703520000000, receivedDateStr=2023-12-26, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795005992423, onlineDateStr=2026-11-18, pubDate=1717948800000, pubDateStr=2024-06-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795005992423, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795005992423, creator=13701087609, updateTime=1795005992423, updator=13701087609, issue=Issue{id=1329914740324807335, tenantId=1146029695717560320, journalId=1319690259887390882, year='2024', volume='55', issue='6', pageStart='743', pageEnd='886', issueExtLink='null', onlineDate='null', pubDate='1717948800000', pubDateStr='2024-06-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795005982713, creator='13701087609', updateTime=1795136155207, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330460723852981013, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329914740324807335, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330460723852981014, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329914740324807335, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=750, endPage=760, ext={EN=ArticleExt(id=1329914781227659454, articleId=1329914781051498685, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Research Progress of Proteolysis Targeting Chimera Drugs, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Proteolysis targeting chimeras(PROTACs) are currently one of the hot spots in antineoplastic agent research. They have efficient and durable anti-tumor effects, good selectivity, and low possible toxicity. This review summarizes the research progress of new PROTAC drugs targeting estrogen receptors, androgen receptors, BCR-ABL, histone deacetylase 4, methyltransferase-like 3.

, authors=Hao QIAN, Weicheng ZHOU, Zhengyan CAI*, authorsList=Hao QIAN, Weicheng ZHOU, Zhengyan CAI, authorCompany=null, correspAuthors=Zhengyan CAI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329914781680644287, articleId=1329914781051498685, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=蛋白降解靶向嵌合体药物的研究进展, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

蛋白降解靶向嵌合体(PROTACs)是当前抗肿瘤药物研究的热点之一,具有抗肿瘤作用高效且持久、选择性好、毒性低的特点。文章总结了靶向雌激素受体、雄激素受体、BCR-ABL、组蛋白去乙酰化酶4以及甲基转移酶样3等PROTACs新药的研究进展。

, authors=钱浩, 周伟澄, 蔡正艳*, authorsList=钱浩, 周伟澄, 蔡正艳, authorCompany=null, correspAuthors=蔡正艳, authorNote=

钱浩(1999—),男,硕士研究生,专业方向:药物化学。

, correspAuthorsNote=
蔡正艳(1979—),女,研究员,博士生导师,从事药物化学研究。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=0OdkKu5s+2YjWgdSjsDU+A==, magXml=yaO/Xz8OfVl0Cjt+4/3KGA==, pdfUrl=null, pdf=fXWlXcqkneX4b2TI+n7z2g==, pdfFileSize=1899634, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=t5/e+69qkm/Ooq0DWxTBOw==, mapNumber=null, fund=null)}, authors=[Author(id=1329914781957468356, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914782024577222, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914781957468356, language=EN, stringName=Hao QIAN, firstName=Hao, middleName=null, lastName=QIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914782087491783, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914781957468356, language=CN, stringName=钱浩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio={"content":"

钱浩(1999—),男,硕士研究生,专业方向:药物化学。

"}, bioImg=null, bioContent=

钱浩(1999—),男,硕士研究生,专业方向:药物化学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914781869387968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, xref=null, ext=[AuthorCompanyExt(id=1329914781873582273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329914781881970882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1329914782154600649, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914782230098123, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782154600649, language=EN, stringName=Weicheng ZHOU, firstName=Weicheng, middleName=null, lastName=ZHOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914782297206988, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782154600649, language=CN, stringName=周伟澄, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914781869387968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, xref=null, ext=[AuthorCompanyExt(id=1329914781873582273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329914781881970882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1329914782372704462, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=caizy2007@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329914782439813328, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782372704462, language=EN, stringName=Zhengyan CAI, firstName=Zhengyan, middleName=null, lastName=CAI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914782502727889, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782372704462, language=CN, stringName=蔡正艳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914781869387968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, xref=null, ext=[AuthorCompanyExt(id=1329914781873582273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329914781881970882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])])], keywords=[Keyword(id=1329914782582419666, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=1, keyword=proteolysis targeting chimera), Keyword(id=1329914782653722835, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=2, keyword=antitumor activity), Keyword(id=1329914782745997524, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=3, keyword=drug discovery), Keyword(id=1329914782808912085, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=4, keyword=clinical study), Keyword(id=1329914782859243734, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=5, keyword=ARV-471), Keyword(id=1329914782922158295, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=6, keyword=ARV-110), Keyword(id=1329914782989267160, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=7, keyword=ARV-766), Keyword(id=1329914783119290585, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=EN, orderNo=8, keyword=research progress), Keyword(id=1329914783190593754, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=1, keyword=蛋白降解靶向嵌合体), Keyword(id=1329914783245119707, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=2, keyword=抗肿瘤活性), Keyword(id=1329914783316422876, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=3, keyword=新药发现), Keyword(id=1329914783404503261, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=4, keyword=临床研究), Keyword(id=1329914783484195038, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=5, keyword=ARV-471), Keyword(id=1329914783559692511, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=6, keyword=ARV-110), Keyword(id=1329914783618412768, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=7, keyword=ARV-766), Keyword(id=1329914783689715937, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, language=CN, orderNo=8, keyword=研究进展)], refs=[Reference(id=1329914783794573538, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=NEKLESA T K, WINKLER J D, CREWS C M.Targeted protein degradation by PROTACs [J].Pharmacol Ther, 2017, 174: 138-144., articleTitle=null, refAbstract=null), Reference(id=1329914783874265315, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=LOPEZ-GIRONA A, MENDY D, ITO T, et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide[J].Leukemia, 2012, 26(11): 2326-2335., articleTitle=null, refAbstract=null), Reference(id=1329914783941374180, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=KRÖNKE J, UDESHI N D, NARLA A, et al.Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells [J].Science, 2014, 343(6168): 301-305., articleTitle=null, refAbstract=null), Reference(id=1329914784008483045, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=PETZOLD G, FISCHER E S, THOMA N H.Structural basis of lenalidomide induced CK1α degradation by the CRL4CRBN ubiquitin ligase [J].Nature, 2016, 532(7597): 127-130., articleTitle=null, refAbstract=null), Reference(id=1329914784096563430, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=JIANG S J, ZHANG M F, SUN J H, et al.Casein kinase 1α: biological mechanisms and theranostic potential [J].Cell Commun Signal, 2018, 16(1): 23., articleTitle=null, refAbstract=null), Reference(id=1329914784159477991, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=NISHIGUCHI G, MASCIBRODA L G, YOUNG S M, et al.Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines [J].Nat Commun, 2024, 15(1): 482., articleTitle=null, refAbstract=null), Reference(id=1329914784226586856, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=FINLEY D.Recognition and processing of ubiquitin-protein conjugates by the proteasome [J].Annu Rev Biochem, 2009, 78: 477-513., articleTitle=null, refAbstract=null), Reference(id=1329914784297890025, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=COUX O, TANAKA K, GOLDBERG A L.Structure and functions of the 20S and 26S proteasomes [J].Annu Rev Biochem, 1996, 65: 801-847., articleTitle=null, refAbstract=null), Reference(id=1329914784369193194, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=LI K, CREWS C M.PROTACs: past, present and future [J].Chem Soc Rev, 2022, 51(12): 5214-5236., articleTitle=null, refAbstract=null), Reference(id=1329914784440496364, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=PICKART C M, EDDINS M J.Ubiquitin: structures, functions, mechanisms [J].Biochim Biophys Acta, 2004, 1695(1-3): 55-72., articleTitle=null, refAbstract=null), Reference(id=1329914784499216621, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=LI W, BENGTSON M H, ULBRICH A, et al.Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle’s dynamics and signaling [J].PloS One, 2008, 3(1): e1487., articleTitle=null, refAbstract=null), Reference(id=1329914784574714094, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=SNYDER L B, FLANAGAN J J, QIAN Y M, et al.The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer [J].Cancer Res, 2021, 81(13_Suppl): 44., articleTitle=null, refAbstract=null), Reference(id=1329914784687960303, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=LIN X, XIANG H, LUO G S.Targeting estrogen receptor α for degradation with PROTACs: a promising approach to overcome endocrine resistance [J].Eur J Med Chem, 2020, 206: 112689., articleTitle=null, refAbstract=null), Reference(id=1329914784780234992, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Arvinas.Arvinas announces ARV-471 achieves a clinical benefit rate of 38% in evaluable patients and continues to show a favorable tolerability profile in its phase 2 expansion trial(VERITAC) [EB/OL].(2022-12-22)[2024-03-01].https://ir.arvinas.com/node/9526/pdf., articleTitle=null, refAbstract=null), Reference(id=1329914784843149553, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=HALFORD B.Arvinas unveils PROTAC structures [J].Chem Eng News, 2021, 99(14): 5., articleTitle=null, refAbstract=null), Reference(id=1329914784906064114, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=SALAMI J, ALABI S, CREWS C M, et al.Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance [J].Commun Biol, 2018, 1: 100., articleTitle=null, refAbstract=null), Reference(id=1329914784981561587, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=SNYDER L B, NEKLESA T, CHEN X, et al.Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer [J].Cancer Res, 2021, 81(13_Suppl): 43., articleTitle=null, refAbstract=null), Reference(id=1329914785061253364, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=NEKLESA T, SNYDER L B, WILLARD R, et al.ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer [J].J Clin Oncol, 2019, 37(7_Suppl): 259., articleTitle=null, refAbstract=null), Reference(id=1329914785132556533, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Arvinas.Arvinas PROTAC® protein degrader bavdegalutamide(ARV-110) continues to demonstrate clinical benefit in men with metastatic castration-resistant prostate cancer [EB/OL].(2022-02-17)[2024-03-01].https://ir.arvinas.com/node/9036/pdf., articleTitle=null, refAbstract=null), Reference(id=1329914785191276790, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Arvinas.Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer [EB/OL].(2023-04-14)[2024-03-01].https://www.arvinas.com/wp-content/uploads/2023/04/discovery-of-arv-766-androgen-receptor-degrading-protac%C2%AE-treatment-metastatic-castration-resistant-prostate-cancer.pdf., articleTitle=null, refAbstract=null), Reference(id=1329914785258385655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Arvinas.Arvinas announces interim data from the ARV-766 phase 1/2 dose escalation and expansion trial showing promising signals of efficacy in late-line mcrpc, including in patients with AR L702H mutations [EB/OL].(2023-06-08)[2024-03-01].https://ir.arvinas.com/node/9911/pdf., articleTitle=null, refAbstract=null), Reference(id=1329914785333883128, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHAO L J, HAN X, LU J F, et al.A highly potent PROTAC androgen receptor(AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo [J].Neoplasia, 2020, 22(10): 522-532., articleTitle=null, refAbstract=null), Reference(id=1329914785400991993, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN X, WANG C, QIN C, et al.Discovery of ARD-69 as a highly potent proteolysis targeting chimera(PROTAC)degrader of androgen receptor(AR) for the treatment of prostate cancer [J].J Med Chem, 2019, 62(2): 941-964., articleTitle=null, refAbstract=null), Reference(id=1329914785468100858, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN X, ZHAO L J, XIANG W G, et al.Discovery of highly potent and efficient PROTAC degraders ofandrogen receptor(AR) by employing weak binding affinity VHL E3 ligase ligands [J].J Med Chem, 2019, 62(24): 11218-11231., articleTitle=null, refAbstract=null), Reference(id=1329914785539404027, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN X, ZHAO L J, XIANG W G, et al.Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer [J].J Med Chem, 2021, 64(17): 12831-12854., articleTitle=null, refAbstract=null), Reference(id=1329914785736536316, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=XIANG W G, ZHAO L J, HAN X, et al.Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer [J].J Med Chem, 2021, 64(18): 13487-13509., articleTitle=null, refAbstract=null), Reference(id=1329914785799450877, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=TALPAZ M, SHAH N P, KANTARJIAN H, et al.Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias [J].N Engl J Med, 2006, 354(24): 2531-2541., articleTitle=null, refAbstract=null), Reference(id=1329914785870754046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHAO Q J, REN C W, LIU L Y, et al.Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von hippel-lindau(VHL) E3 ubiquitin ligase [J].J Med Chem, 2019, 62(20): 9281-9298., articleTitle=null, refAbstract=null), Reference(id=1329914785937862911, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=张頔,穆冠群,杨洋.组蛋白去乙酰化酶4与人类疾病[J].中国生物化学与分子生物学报,2017,33(10):999-1007., articleTitle=null, refAbstract=null), Reference(id=1329914786025943296, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=南昌市第一医院.一种靶向降解HDAC4的化合物及其制备方法和应用:中国,117624134A [P].2024-03-01., articleTitle=null, refAbstract=null), Reference(id=1329914786088857857, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=刘彦希,刘家琪,关宗彬,等.甲基转移酶METTL3与肿瘤相关性研究进展[J].吉林医药学院学报,2023,44(2):121-124., articleTitle=null, refAbstract=null), Reference(id=1329914786160161026, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=中国科学院上海药物研究所.一类靶向降解METTL3的双功能化合物和药物组合物及应用:中国,117586340A [P].2024-02-23., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329914781869387968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, xref=null, ext=[AuthorCompanyExt(id=1329914781873582273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329914781881970882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2024.06.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2024.06.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2024.06.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2024.06.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1717948800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
蛋白降解靶向嵌合体药物的研究进展
钱浩 , 周伟澄 , 蔡正艳 *
中国医药工业杂志 | 综述 2024,55(6): 750-760
收起
收藏切换
中国医药工业杂志 |综述 2024 , 55 (6) : 750 -760
蛋白降解靶向嵌合体药物的研究进展
全屏
[Author(id=1329914781957468356, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914782024577222, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914781957468356, language=EN, stringName=Hao QIAN, firstName=Hao, middleName=null, lastName=QIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914782087491783, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914781957468356, language=CN, stringName=钱浩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio={"content":"

钱浩(1999—),男,硕士研究生,专业方向:药物化学。

"}, bioImg=null, bioContent=

钱浩(1999—),男,硕士研究生,专业方向:药物化学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914781869387968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, xref=null, ext=[AuthorCompanyExt(id=1329914781873582273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329914781881970882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1329914782154600649, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914782230098123, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782154600649, language=EN, stringName=Weicheng ZHOU, firstName=Weicheng, middleName=null, lastName=ZHOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914782297206988, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782154600649, language=CN, stringName=周伟澄, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914781869387968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, xref=null, ext=[AuthorCompanyExt(id=1329914781873582273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329914781881970882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])]), Author(id=1329914782372704462, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=caizy2007@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329914782439813328, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782372704462, language=EN, stringName=Zhengyan CAI, firstName=Zhengyan, middleName=null, lastName=CAI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914782502727889, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, authorId=1329914782372704462, language=CN, stringName=蔡正艳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914781869387968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, xref=null, ext=[AuthorCompanyExt(id=1329914781873582273, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1329914781881970882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914781051498685, companyId=1329914781869387968, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203)])])]
钱浩, 周伟澄, 蔡正艳*
作者信息
  • 中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203
通讯作者:
蔡正艳(1979—),女,研究员,博士生导师,从事药物化学研究。E-mail:
作者简介:

钱浩(1999—),男,硕士研究生,专业方向:药物化学。

Research Progress of Proteolysis Targeting Chimera Drugs
Hao QIAN, Weicheng ZHOU, Zhengyan CAI*
Affiliations
  • National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, State Institute of Pharmaceutical Industry, Shanghai 201203
出版时间: 2024-06-10 doi: 10.16522/j.cnki.cjph.2024.06.002
文章导航
收藏切换

蛋白降解靶向嵌合体(PROTACs)是当前抗肿瘤药物研究的热点之一,具有抗肿瘤作用高效且持久、选择性好、毒性低的特点。文章总结了靶向雌激素受体、雄激素受体、BCR-ABL、组蛋白去乙酰化酶4以及甲基转移酶样3等PROTACs新药的研究进展。

蛋白降解靶向嵌合体  /  抗肿瘤活性  /  新药发现  /  临床研究  /  ARV-471  /  ARV-110  /  ARV-766  /  研究进展

Proteolysis targeting chimeras(PROTACs) are currently one of the hot spots in antineoplastic agent research. They have efficient and durable anti-tumor effects, good selectivity, and low possible toxicity. This review summarizes the research progress of new PROTAC drugs targeting estrogen receptors, androgen receptors, BCR-ABL, histone deacetylase 4, methyltransferase-like 3.

proteolysis targeting chimera  /  antitumor activity  /  drug discovery  /  clinical study  /  ARV-471  /  ARV-110  /  ARV-766  /  research progress
钱浩, 周伟澄, 蔡正艳. 蛋白降解靶向嵌合体药物的研究进展. 中国医药工业杂志, 2024 , 55 (6) : 750 -760 . DOI: 10.16522/j.cnki.cjph.2024.06.002
Hao QIAN, Weicheng ZHOU, Zhengyan CAI. Research Progress of Proteolysis Targeting Chimera Drugs[J]. Chinese Journal of Pharmaceuticals, 2024 , 55 (6) : 750 -760 . DOI: 10.16522/j.cnki.cjph.2024.06.002

参考文献 引证文献
排序方式:
[1]
NEKLESA T K, WINKLER J D, CREWS C M.Targeted protein degradation by PROTACs [J].Pharmacol Ther, 2017, 174: 138-144.
[2]
LOPEZ-GIRONA A, MENDY D, ITO T, et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide[J].Leukemia, 2012, 26(11): 2326-2335.
[3]
KRÖNKE J, UDESHI N D, NARLA A, et al.Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells [J].Science, 2014, 343(6168): 301-305.
[4]
PETZOLD G, FISCHER E S, THOMA N H.Structural basis of lenalidomide induced CK1α degradation by the CRL4CRBN ubiquitin ligase [J].Nature, 2016, 532(7597): 127-130.
[5]
JIANG S J, ZHANG M F, SUN J H, et al.Casein kinase 1α: biological mechanisms and theranostic potential [J].Cell Commun Signal, 2018, 16(1): 23.
[6]
NISHIGUCHI G, MASCIBRODA L G, YOUNG S M, et al.Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines [J].Nat Commun, 2024, 15(1): 482.
[7]
FINLEY D.Recognition and processing of ubiquitin-protein conjugates by the proteasome [J].Annu Rev Biochem, 2009, 78: 477-513.
[8]
COUX O, TANAKA K, GOLDBERG A L.Structure and functions of the 20S and 26S proteasomes [J].Annu Rev Biochem, 1996, 65: 801-847.
[9]
LI K, CREWS C M.PROTACs: past, present and future [J].Chem Soc Rev, 2022, 51(12): 5214-5236.
[10]
PICKART C M, EDDINS M J.Ubiquitin: structures, functions, mechanisms [J].Biochim Biophys Acta, 2004, 1695(1-3): 55-72.
[11]
LI W, BENGTSON M H, ULBRICH A, et al.Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle’s dynamics and signaling [J].PloS One, 2008, 3(1): e1487.
[12]
SNYDER L B, FLANAGAN J J, QIAN Y M, et al.The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer [J].Cancer Res, 2021, 81(13_Suppl): 44.
[13]
LIN X, XIANG H, LUO G S.Targeting estrogen receptor α for degradation with PROTACs: a promising approach to overcome endocrine resistance [J].Eur J Med Chem, 2020, 206: 112689.
[14]
Arvinas.Arvinas announces ARV-471 achieves a clinical benefit rate of 38% in evaluable patients and continues to show a favorable tolerability profile in its phase 2 expansion trial(VERITAC) [EB/OL].(2022-12-22)[2024-03-01].https://ir.arvinas.com/node/9526/pdf.
[15]
HALFORD B.Arvinas unveils PROTAC structures [J].Chem Eng News, 2021, 99(14): 5.
[16]
SALAMI J, ALABI S, CREWS C M, et al.Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance [J].Commun Biol, 2018, 1: 100.
[17]
SNYDER L B, NEKLESA T, CHEN X, et al.Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer [J].Cancer Res, 2021, 81(13_Suppl): 43.
[18]
NEKLESA T, SNYDER L B, WILLARD R, et al.ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer [J].J Clin Oncol, 2019, 37(7_Suppl): 259.
[19]
Arvinas.Arvinas PROTAC® protein degrader bavdegalutamide(ARV-110) continues to demonstrate clinical benefit in men with metastatic castration-resistant prostate cancer [EB/OL].(2022-02-17)[2024-03-01].https://ir.arvinas.com/node/9036/pdf.
[20]
Arvinas.Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer [EB/OL].(2023-04-14)[2024-03-01].https://www.arvinas.com/wp-content/uploads/2023/04/discovery-of-arv-766-androgen-receptor-degrading-protac%C2%AE-treatment-metastatic-castration-resistant-prostate-cancer.pdf.
[21]
Arvinas.Arvinas announces interim data from the ARV-766 phase 1/2 dose escalation and expansion trial showing promising signals of efficacy in late-line mcrpc, including in patients with AR L702H mutations [EB/OL].(2023-06-08)[2024-03-01].https://ir.arvinas.com/node/9911/pdf.
[22]
ZHAO L J, HAN X, LU J F, et al.A highly potent PROTAC androgen receptor(AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo [J].Neoplasia, 2020, 22(10): 522-532.
[23]
HAN X, WANG C, QIN C, et al.Discovery of ARD-69 as a highly potent proteolysis targeting chimera(PROTAC)degrader of androgen receptor(AR) for the treatment of prostate cancer [J].J Med Chem, 2019, 62(2): 941-964.
[24]
HAN X, ZHAO L J, XIANG W G, et al.Discovery of highly potent and efficient PROTAC degraders ofandrogen receptor(AR) by employing weak binding affinity VHL E3 ligase ligands [J].J Med Chem, 2019, 62(24): 11218-11231.
[25]
HAN X, ZHAO L J, XIANG W G, et al.Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer [J].J Med Chem, 2021, 64(17): 12831-12854.
[26]
XIANG W G, ZHAO L J, HAN X, et al.Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer [J].J Med Chem, 2021, 64(18): 13487-13509.
[27]
TALPAZ M, SHAH N P, KANTARJIAN H, et al.Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias [J].N Engl J Med, 2006, 354(24): 2531-2541.
[28]
ZHAO Q J, REN C W, LIU L Y, et al.Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von hippel-lindau(VHL) E3 ubiquitin ligase [J].J Med Chem, 2019, 62(20): 9281-9298.
[29]
张頔,穆冠群,杨洋.组蛋白去乙酰化酶4与人类疾病[J].中国生物化学与分子生物学报,2017,33(10):999-1007.
[30]
南昌市第一医院.一种靶向降解HDAC4的化合物及其制备方法和应用:中国,117624134A [P].2024-03-01.
[31]
刘彦希,刘家琪,关宗彬,等.甲基转移酶METTL3与肿瘤相关性研究进展[J].吉林医药学院学报,2023,44(2):121-124.
[32]
中国科学院上海药物研究所.一类靶向降解METTL3的双功能化合物和药物组合物及应用:中国,117586340A [P].2024-02-23.
2024年第55卷第6期
24
5
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2024.06.002
  • 接收时间:2023-12-26
  • 首发时间:2026-11-18
  • 出版时间:2024-06-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-12-26
基金
作者信息
    中国医药工业研究总院上海医药工业研究院,先导物成药性研究全国重点实验室,上海 201203

通讯作者:

蔡正艳(1979—),女,研究员,博士生导师,从事药物化学研究。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2024.06.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏